Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial
Jump to navigation
Jump to search
Introduction
Study characteristics:
- 8,500 patients ages 60-80 in China[1]
Treatment
- target systolic blood pressure 110-130 mm Hg
Results:
- 26% reduction in risk of stroke, acute myocardial infarction, hospitalization for unstable angina, acute decompensated heart failure, coronary revascularization, atrial fibrillation, or cardiovascular death
- benefit independent of baseline diastolic blood pressure[2]
- no mention of all-cause mortality, quality of life, cognition or falls
More general terms
Additional terms
References
- ↑ 1.0 1.1 Phend C Lower BP Targets Again Affirmed in Major Trial. STEP trial from China shows major benefits in older population. MedPage Today August 30, 2021 https://www.medpagetoday.com/meetingcoverage/esc/94277
Zhang W, Zhang S, Deng Y et al Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. August 30, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34491661 https://www.nejm.org/doi/full/10.1056/NEJMoa2111437 - ↑ 2.0 2.1 Yang R, Huang R, Zhang L et al. Influence of baseline diastolic blood pressure on the effects of intensive blood pressure lowering: Results from the STEP randomized trial. Hypertension 2023 Oct 10; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/37814892 https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.123.21892